Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Apr;51(2):531-534.
doi: 10.1007/s15010-022-01922-8. Epub 2022 Sep 15.

Neutralization of SARS-CoV-2 Omicron BA.1, BA.4, and BA.5 by primary ChAdOx1 nCoV-19, mRNA-1273, MVC-COV1901 and booster mRNA-1273 vaccination

Yuag-Meng Liu  1   2 , Yu-Lin Lee  2 , Chun-Eng Liu  2 , Yi-Chun Chen  2 , Ni Tien #  3   4 , Wen-Chi Su #  5   6   7
Affiliations
Comment

Neutralization of SARS-CoV-2 Omicron BA.1, BA.4, and BA.5 by primary ChAdOx1 nCoV-19, mRNA-1273, MVC-COV1901 and booster mRNA-1273 vaccination

Yuag-Meng Liu et al. Infection. 2023 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Figures

Fig. 1
Fig. 1
Neutralization of SARS-CoV-2 pseudoviruses in sera from recipients of different primary vaccine regimens and mRNA-1273 booster. Each group consists of 30 health volunteers who had received two doses of ChAdOx1 nCoV-19, mRNA-1273, or MVC-COV1901 vaccines. Serum samples were collected 1 month after the 50-μg mRNA-1273 booster dose. Antibody titers against wild-type and Omicron pseudoviruses were measured using pseudovirus neutralization assay. The 50% inhibitory dilution (ID50) was determined using the percentage of neutralization at different dilutions to determine the titers of sera at which half amounts of pseudotyped viruses are inhibited. The GMTs (central horizontal lines) and 95% confidence intervals (upper and lower horizontal lines) are plotted. GMTs of each group are given above each column. Each symbol represents individual vaccine recipients. This assay had a lower limit of detection of 40 (dotted line). A two-sided Kruskal–Wallis test with Dunn’s multiple comparisons was conducted between different types of vaccinated individuals. **P < 0.01, ***p < 0.001
See this image and copyright information in PMC

Comment on

  • Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.
    Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, Gower C, Kall M, Groves N, O'Connell AM, Simons D, Blomquist PB, Zaidi A, Nash S, Iwani Binti Abdul Aziz N, Thelwall S, Dabrera G, Myers R, Amirthalingam G, Gharbia S, Barrett JC, Elson R, Ladhani SN, Ferguson N, Zambon M, Campbell CNJ, Brown K, Hopkins S, Chand M, Ramsay M, Lopez Bernal J. Andrews N, et al. N Engl J Med. 2022 Apr 21;386(16):1532-1546. doi: 10.1056/NEJMoa2119451. Epub 2022 Mar 2. N Engl J Med. 2022. PMID: 35249272 Free PMC article.

References

    1. Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, et al. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med. 2022 doi: 10.1038/s41591-022-01911-2. - DOI - PMC - PubMed
    1. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022 doi: 10.1056/NEJMoa2119451. - DOI - PMC - PubMed
    1. Kuo T-Y, Lin M-Y, Coffman RL, Campbell JD, Traquina P, Lin Y-J, et al. Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19. Sci Rep. 2020;10:20085. doi: 10.1038/s41598-020-77077-z. - DOI - PMC - PubMed
    1. Hsieh S-M, Chang S-C, Cheng H-Y, Shih S-R, Lien CE. The reactogenicity and immunogenicity of a booster dose after the second dose of a protein subunit vaccine MVC-COV1901: an extension to an open-label, dose-escalation, and non-randomized phase 1 study. medRxiv. 2021 doi: 10.1101/2021.12.01.21267115. - DOI - PubMed
    1. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27:1205–1211. doi: 10.1038/s41591-021-01377-8. - DOI - PubMed